|
Lock procedure for expensive medicinal products
|
|
1
|
55
|
November 1, 2024
|
|
Is the new EU pharma legislation a threat to academic drug development?
|
|
0
|
24
|
September 20, 2024
|
|
Looking for a detailed overview of the drug discovery, development and deployment journey of biologics?
|
|
0
|
34
|
September 17, 2024
|
|
Looking for a detailed overview of the drug discovery, development and deployment journey of small molecules?
|
|
0
|
42
|
September 17, 2024
|
|
Where can I ask for scientific advice for my clinical studies?
|
|
1
|
26
|
September 10, 2024
|
|
Advice at HealthCare Institute (ZIN)
|
|
1
|
44
|
September 9, 2024
|
|
Data protection in personalized medicine
|
|
0
|
23
|
July 31, 2024
|
|
AI for drug combinations
|
|
0
|
24
|
August 21, 2024
|
|
Clinical trial for an extremely rare disease
|
|
1
|
25
|
August 21, 2024
|
|
Market approval guidelines
|
|
1
|
29
|
August 21, 2024
|
|
Clinical trial application review
|
|
1
|
30
|
August 21, 2024
|
|
AI and prediction of side effects
|
|
0
|
22
|
July 31, 2024
|
|
Is it mandatory to include an IDMC/DSMB charter for the Dose Escalation Committee (DEC) for a phase I clinical study?
|
|
0
|
40
|
July 2, 2024
|
|
CTR - Is a legal representative required in the Netherlands
|
|
0
|
26
|
May 30, 2024
|
|
Retention period of data relating to traceability of ATMPs
|
|
0
|
24
|
May 30, 2024
|
|
Language on the label
|
|
0
|
20
|
May 30, 2024
|
|
Registration of unautorhised IMP in Extended EudraVigilance medicinal product dictionary (XEVMPD)
|
|
0
|
17
|
May 30, 2024
|
|
SUSAR reporting
|
|
0
|
23
|
May 13, 2024
|